Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

BOTHELL, WA, and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the two-year survival rate from a Phase 1/2 clinical trial of OGX-011 in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). At two years, 30% of patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%.

For comparison, published studies using a platinum-based regimen plus gemcitabine as first-line chemotherapy for advanced NSCLC reported median survivals of 8 to 11 months and one-year survival rates of 33% to 43%. Market approval for Avastin plus paclitaxel and carboplatin chemotherapy for NSCLC was based on results showing a median survival of 12.3 months compared to 10.3 months for patients treated with chemotherapy alone. Survival rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44% at one year and 23% versus 15% at two years, respectively.

"The two-year survival rate of 30% in our Phase 1/2 NSCLC study compares favorably to the survival reported for Avastin plus paclitaxel and carboplatin chemotherapy," said Scott Cormack, president and CEO of OncoGenex. "These data remain consistent with our Phase 2 data in prostate cancer suggesting that OGX-011 when added to chemotherapy may improve survival by blocking the production of clusterin, the protein associated with treatment resistance in various cancers."

    Non-Small Cell Lung Cancer Phase 1/2 Study Design with Updated Results as
    of January 23, 2009

This single-arm, open-label study enrolled 81 patients with Stage IIIB (18 percent) or Stage IV (82 percent) NSCLC who were treated with OGX-011 in combination w
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced ... Form 20-F for the fiscal year ended December 31, ... The annual report on Form 20-F contains information regarding ... the area of cancer immune checkpoints. This project aims ... specificity and binding in targeting certain identified immune checkpoints. ...
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
(Date:5/4/2015)...   Tocagen Inc. , a clinical-stage immuno-oncology ... ongoing investigational studies were presented at the 11 th ... of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) ... Washington, D.C. In addition, ... FDA and continues to advance towards initiation of ...
(Date:5/1/2015)... N.C. (PRWEB) May 01, 2015 ... Charlotte (UNC Charlotte) spin-out company, announced that Pinku Mukherjee, ... the UNC Board of Governors’ highest faculty honor. ... to humanity’s welfare , for her innovative research and ... Max Gardner Award represents a crowning moment in my ...
Breaking Biology Technology:Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2
... , Agencourts RNAClean ... method for purifying nucleic acid products generated in common enzymatic , ... The kit is formatted for microarray , gene ... automated formats. RNAClean eliminates the need for vacuum filtration or ...
... , , RNA later is a ... that stabilizes and protects cellular RNA in fresh , ... specifically for use with frozen tissues - see "<A , ... Grinding Frozen Tissue " for more information.) ...
... Gene arrays are solid ... collection of gene-specific nucleic acids have been placed at , ... array analysis, a nucleic acid-containing sample is labeled , ... targets , on the array. ...
Cached Biology Technology:RNAClean - RNA & cDNA in vitro Reaction Purification 2RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 2RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 3RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 4RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 5RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 6RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 7Array Analysis: The Basics 2Array Analysis: The Basics 3Array Analysis: The Basics 4Array Analysis: The Basics 5
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... becomes higher, the hair at the back of the man's ... greater or lesser hair loss. There are hardly any successful ... , It has long been suspected that hereditary factors are ... was unclear which genes are involved. The researchers in the ...
... team from Yale School of Medicine has glimpsed one ... work, performed in collaboration with English and French scientists, ... internalize cell surface receptors. , All cells traffic protein ... most important routes for cargo internalization is clathrin mediated ...
... brain cells less than half the size of a pencil eraser ... when it's time to go to sleep. The same cells also ... zones. , The human circadian clock, comprised of about 20,000 time-keeping ... about 30 years ago. Now, a researcher at the University of ...
Cached Biology News:Tendency to hair loss inherited from the mother 2Researchers develop assay that could be applied to drug screening 2The circadian clock: Understanding nature's timepiece 2
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
...
Biology Products: